<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36834923</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>09</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Role of New 3D Pathology and Lymphocyte Expression of Interstitial Inflammation in Pediatric-Onset Lupus Nephritis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3512</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24043512</ELocationID><Abstract><AbstractText>Lupus nephritis (LN) is a common and severe manifestation of pediatric-onset systemic lupus erythematosus (pSLE). It is one of the major causes of long-term glucocorticoid/immune suppressants use in pSLE. It causes long-term glucocorticoid/immune suppressants use and even end-stage renal disease (ESRD) in pSLE. It is now well known that high chronicity, especially the tubulointerstitial components in the renal biopsy, predicts a poor renal outcome. Interstitial inflammation (II), a component of activity in LN pathology, can be an early predictor for the renal outcome. With the advent of 3D pathology and CD19-targeted CAR-T cell therapy in the 2020s, the present study focuses on detailed pathology and B cell expression in II. We recruited 48 pSLE patients with class III/IV LN to analyze the risk of ESRD based on different II scores. We also studied 3D renal pathology and immunofluorescence (IF) staining of CD3, 19, 20, and 138 in patients with a high II score but low chronicity. Those pSLE LN patients with II scores of 2 or 3 showed a higher risk for ESRD (<i>p</i> = 0.003) than those with II scores of 0 or 1. Excluding patients with chronicity &gt;3, high II scores still carried a higher risk for ESRD (<i>p</i> = 0.005). Checking the average scores from the renal specimens from different depths, the II, and chronicity showed good consistency between 3D and 2D pathology (interclass correlation coefficient [ICC], II = 0.91, <i>p</i> = 0.0015; chronicity = 0.86, <i>p</i> = 0.024). However, the sum of tubular atrophy plus interstitial fibrosis showed no good consistency (ICC = 0.79, <i>p</i> = 0.071). The selected LN patients with negative CD19/20 IF stains showed scattered CD3 infiltration and a different IF pattern of Syndecan-1 expression. Our study provides unique data in LN, including 3D pathology and different in situ Syndecan-1 patterns in LN patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yung-Chieh</ForeName><Initials>YC</Initials><Identifier Source="ORCID">0000-0003-2945-4404</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Yong-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Taichung Veterans General Hospital, Taichung 40705, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jun-Pen</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Lin-Shien</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0003-4770-3208</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Taichung Veterans General Hospital, Taichung 40705, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 40227, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TCVGH-1116504C</GrantID><Agency>Taichung Veterans General Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053668">Syndecan-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053668" MajorTopicYN="N">Syndecan-1</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3D pathology</Keyword><Keyword MajorTopicYN="N">Syndecan-1</Keyword><Keyword MajorTopicYN="N">interstitial inflammation</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">pediatric-onset systemic lupus erythematosus (pSLE)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>2</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36834923</ArticleId><ArticleId IdType="pmc">PMC9967023</ArticleId><ArticleId IdType="doi">10.3390/ijms24043512</ArticleId><ArticleId IdType="pii">ijms24043512</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hanly J.G., O&#x2019;Keeffe A.G., Su L., Urowitz M.B., Romero-Diaz J., Gordon C., Bae S.C., Bernatsky S., Clarke A.E., Wallace D.J., et al. The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology. 2016;55:252&#x2013;262. doi: 10.1093/rheumatology/kev311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev311</ArticleId><ArticleId IdType="pmc">PMC4939728</ArticleId><ArticleId IdType="pubmed">26342222</ArticleId></ArticleIdList></Reference><Reference><Citation>Maningding E., Dall&#x2019;Era M., Trupin L., Murphy L.B., Yazdany J. Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project. Arthritis Care Res. 2020;72:622&#x2013;629. doi: 10.1002/acr.23887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23887</ArticleId><ArticleId IdType="pmc">PMC6872905</ArticleId><ArticleId IdType="pubmed">31115180</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez Cruz B., Alonso F., Calvo Al&#xe9;n J., Pego-Reigosa J.M., L&#xf3;pez-Longo F.J., Galindo-Izquierdo M., Oliv&#xe9; A., Tomero E., Horcada L., Uriarte E., et al. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry) Lupus. 2020;29:27&#x2013;36. doi: 10.1177/0961203319889667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319889667</ArticleId><ArticleId IdType="pubmed">31801040</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston B., Bonner A., Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: A meta-analysis. Lupus. 2011;20:1345&#x2013;1355. doi: 10.1177/0961203311416694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311416694</ArticleId><ArticleId IdType="pubmed">21951943</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparotto M., Gatto M., Binda V., Doria A., Moroni G. Lupus nephritis: Clinical presentations and outcomes in the 21st century. Rheumatology. 2020;59:v39&#x2013;v51. doi: 10.1093/rheumatology/keaa381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa381</ArticleId><ArticleId IdType="pmc">PMC7751166</ArticleId><ArticleId IdType="pubmed">33280015</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria A., Amoura Z., Cervera R., Khamastha M.A., Schneider M., Richter J., Guillemin F., Kobelt G., Maurel F., Garofano A., et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann. Rheum. Dis. 2014;73:154&#x2013;160. doi: 10.1136/annrheumdis-2012-202443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202443</ArticleId><ArticleId IdType="pubmed">23264339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema I.M., Wilhelmus S., Alpers C.E., Bruijn J.A., Colvin R.B., Cook H.T., D&#x2019;Agati V.D., Ferrario F., Haas M., Jennette J.C., et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93:789&#x2013;796. doi: 10.1016/j.kint.2017.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson P.C., Kashgarian M., Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin. Kidney J. 2018;11:207&#x2013;218. doi: 10.1093/ckj/sfx093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfx093</ArticleId><ArticleId IdType="pmc">PMC5888814</ArticleId><ArticleId IdType="pubmed">29644061</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes M.F., Mardones C., Xipell M., Blasco M., Sol&#xe9; M., Espinosa G., Garc&#xed;a-Herrera A., Cervera R., Quintana L.F. The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. J. Nephrol. 2021;34:1897&#x2013;1905. doi: 10.1007/s40620-021-01007-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-021-01007-z</ArticleId><ArticleId IdType="pubmed">33721269</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsuwaida A.O. Interstitial inflammation and long-term renal outcomes in lupus nephritis. Lupus. 2013;22:1446&#x2013;1454. doi: 10.1177/0961203313507986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313507986</ArticleId><ArticleId IdType="pubmed">24097970</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnink E.C., Teng Y.K.O., Wilhelmus S., Almekinders M., Wolterbeek R., Cransberg K., Bruijn J.A., Bajema I.M. Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. Clin. J. Am. Soc. Nephrol. CJASN. 2017;12:734&#x2013;743. doi: 10.2215/cjn.10601016.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/cjn.10601016</ArticleId><ArticleId IdType="pmc">PMC5477219</ArticleId><ArticleId IdType="pubmed">28473317</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang A., Henderson S.G., Brandt D., Liu N., Guttikonda R., Hsieh C., Kaverina N., Utset T.O., Meehan S.M., Quigg R.J., et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 2011;186:1849&#x2013;1860. doi: 10.4049/jimmunol.1001983.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001983</ArticleId><ArticleId IdType="pmc">PMC3124090</ArticleId><ArticleId IdType="pubmed">21187439</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinloch A.J., Chang A., Ko K., Henry Dunand C.J., Henderson S., Maienschein-Cline M., Kaverina N., Rovin B.H., Salgado Ferrer M., Wolfgeher D., et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol. 2014;66:3359&#x2013;3370. doi: 10.1002/art.38888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38888</ArticleId><ArticleId IdType="pmc">PMC4264660</ArticleId><ArticleId IdType="pubmed">25306868</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham R., Durkee M.S., Ai J., Veselits M., Casella G., Asano Y., Chang A., Ko K., Oshinsky C., Peninger E., et al. Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis. J. Clin. Investig. 2022;132:e155350. doi: 10.1172/jci155350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci155350</ArticleId><ArticleId IdType="pmc">PMC9246394</ArticleId><ArticleId IdType="pubmed">35608910</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I., Gomez A., Lindblom J., Chow J.W., Sj&#xf6;wall C., Sciascia S., Gatto M. B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab. Int. J. Mol. Sci. 2022;23:13941. doi: 10.3390/ijms232213941.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232213941</ArticleId><ArticleId IdType="pmc">PMC9698874</ArticleId><ArticleId IdType="pubmed">36430417</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y.Y., Lin C.W., Enikolopov G., Sibley E., Chiang A.S., Tang S.C. Microtome-free 3-dimensional confocal imaging method for visualization of mouse intestine with subcellular-level resolution. Gastroenterology. 2009;137:453&#x2013;465. doi: 10.1053/j.gastro.2009.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2009.05.008</ArticleId><ArticleId IdType="pmc">PMC2894712</ArticleId><ArticleId IdType="pubmed">19447107</ArticleId></ArticleIdList></Reference><Reference><Citation>Crickx E., Tamirou F., Huscenot T., Costedoat-Chalumeau N., Rabant M., Karras A., Robbins A., Fadeev T., Le Guern V., Remy P., et al. Molecular Signatures of Kidney Antibody-Secreting Cells in Lupus Patients with Active Nephritis Upon Immunosuppressive Therapy. Arthritis Rheumatol. 2021;73:1461&#x2013;1466. doi: 10.1002/art.41703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41703</ArticleId><ArticleId IdType="pubmed">33645886</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.J., Kim J.Y., Baek I.W., Kim W.U., Cho C.S. Elevated serum levels of syndecan-1 are associated with renal involvement in patients with systemic lupus erythematosus. J. Rheumatol. 2015;42:202&#x2013;209. doi: 10.3899/jrheum.140568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.140568</ArticleId><ArticleId IdType="pubmed">25512478</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K.Y.C., Yung S., Chau M.K.M., Tang C.S.O., Yap D.Y.H., Tang A.H.N., Ying S.K.Y., Lee C.K., Chan T.M. Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis. Rheumatology. 2021;60:737&#x2013;750. doi: 10.1093/rheumatology/keaa370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa370</ArticleId><ArticleId IdType="pubmed">32793966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mujtahedi S.S., Yigitbilek F., Benavides X., Merzkani M.A., Ozdogan E., Abozied O., Moore N.A., Park W.D., Stegall M.D. Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture. Transpl. Immunol. 2022;75:101726. doi: 10.1016/j.trim.2022.101726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trim.2022.101726</ArticleId><ArticleId IdType="pubmed">36183942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S., Radin M., Yazdany J., Levy R.A., Roccatello D., Dall&#x2019;Era M., Cuadrado M.J. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. Autoimmun. Rev. 2017;16:287&#x2013;293. doi: 10.1016/j.autrev.2017.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.01.010</ArticleId><ArticleId IdType="pubmed">28147262</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M., Saccon F., Andreoli L., Bartoloni E., Benvenuti F., Bortoluzzi A., Bozzolo E., Brunetta E., Canti V., Cardinaletti P., et al. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. J. Autoimmun. 2021;124:102729. doi: 10.1016/j.jaut.2021.102729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102729</ArticleId><ArticleId IdType="pubmed">34600347</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Kostopoulou M., Cheema K., Anders H.J., Aringer M., Bajema I., Boletis J., Frangou E., Houssiau F.A., Hollis J., et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 2020;79:713&#x2013;723. doi: 10.1136/annrheumdis-2020-216924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn B.H., McMahon M.A., Wilkinson A., Wallace W.D., Daikh D.I., Fitzgerald J.D., Karpouzas G.A., Merrill J.T., Wallace D.J., Yazdany J., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797&#x2013;808. doi: 10.1002/acr.21664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21664</ArticleId><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L., Burns M., Durek P., Heinz G.A., Heinrich F., Garantziotis P., Enghard P., Richter U., Biesen R., Schneider U., et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N. Engl. J. Med. 2020;383:1149&#x2013;1155. doi: 10.1056/NEJMoa2023325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023325</ArticleId><ArticleId IdType="pubmed">32937047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A., M&#xfc;ller F., Mougiakakos D., B&#xf6;ltz S., Wilhelm A., Aigner M., V&#xf6;lkl S., Simon D., Kleyer A., Munoz L., et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022;28:2124&#x2013;2132. doi: 10.1038/s41591-022-02017-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId><ArticleId IdType="pubmed">36109639</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening J.J., D&#x2019;Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., Balow J.E., Bruijn J.A., Cook T., Ferrario F., et al. International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>